350
Participants
Start Date
September 26, 2013
Primary Completion Date
November 7, 2016
Study Completion Date
June 1, 2017
Percutaneous Coronary Intervention
Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
Mount Sinai New York, New York
Allegheny General Hospital, Pittsburgh
University Pittsburg MC - Hamot, Erie
MedStar Washington Hospital, Washington D.C.
John Hopkins, Baltimore
North Carolina Heart & Vascular Specialists, Raleigh
Duke University Medical Center, Durham
East Carolina University, Greenville
Georgia Regents Research Institute, Augusta
Cardiovascular Institute of NW Florida, Panama City
Mount Sinai Medical Center Heart Institute, Miami Beach
Clearwater Cardiovascular & Interventional Consultants, Clearwater
University of Tennessee, Memphis
OhioHealth Research Institute, Columbus
Indiana University, Indianapolis
Beaumont Hospital, Royal Oak
McLaren Bay Regional, Bay City
University of Chicago Medical Center, Chicago
Prairie Education & Research Cooperative, Springfield
Barnes Jewish Hospital, St Louis
Saint Luke's, Kansas City
Boone Hospital, Columbia
Arkansas Heart Hospital, Little Rock
St. John Health System, Tulsa
Providence Health Center, Waco
Houston Methodist Research Institute, Houston
Mission Research Institute, New Braunfels
Glendale Adventist Medical Center, Glendale
Hartford Hospital, Hartford
Tufts Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Baystate Medical Center, Springfield
Hackensack University Medical Center, Hackensack
Jersey Shore Medical Center, Neptune City
Lead Sponsor
Abbott Medical Devices
INDUSTRY